0000899243-18-016285.txt : 20180612 0000899243-18-016285.hdr.sgml : 20180612 20180612202630 ACCESSION NUMBER: 0000899243-18-016285 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180608 FILED AS OF DATE: 20180612 DATE AS OF CHANGE: 20180612 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lowrance David L CENTRAL INDEX KEY: 0001408498 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32157 FILM NUMBER: 18895675 MAIL ADDRESS: STREET 1: 422 WILLIAM WALLACE DRIVE CITY: FRANKLIN STATE: TN ZIP: 37064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Savara Inc CENTRAL INDEX KEY: 0001160308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841318182 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY STREET 2: SUITE 150 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: 512-614-1848 MAIL ADDRESS: STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY STREET 2: SUITE 150 CITY: AUSTIN STATE: TX ZIP: 78746 FORMER COMPANY: FORMER CONFORMED NAME: Mast Therapeutics, Inc. DATE OF NAME CHANGE: 20130312 FORMER COMPANY: FORMER CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030613 FORMER COMPANY: FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010928 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-06-08 0 0001160308 Savara Inc SVRA 0001408498 Lowrance David L 6836 BEE CAVE ROAD, BUILDING III SUITE 200 AUSTIN TX 78746 0 1 0 0 Chief Financial Officer Common Stock 2018-06-08 4 S 0 675 12.1283 D 23080 D Common Stock 2018-06-11 4 S 0 700 12.0516 D 22380 D Common Stock 2018-06-12 4 S 0 3900 12.0781 D 18480 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2017. The price is a weighted average sale price. The sale prices ranged from $12.00 to $12.40. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. The price is a weighted average sale price. The sale prices ranged from $12.00 to $12.2575. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. The price is a weighted average sale price. The sale prices ranged from $12.00 to $12.23. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. /s/ David Lowrance 2018-06-12